Literature DB >> 1921984

Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity.

G L Forrest1, S Akman, J Doroshow, H Rivera, W D Kaplan.   

Abstract

Carbonyl reductase (NADPH: secondary-alcohol oxidoreductase; EC 1.1.1.184), a widely distributed NADPH-dependent enzyme considered as both an aldo-keto reductase and a quinone reductase, was cloned from a human liver genomic library and transiently expressed in COS7 cells. The gene contains 3142 bases comprising three exons and two introns. The absence of a CAAT and TATA box and the presence of a GC-rich island are characteristic of many "housekeeping" genes. Transient expression of the genomic gene in COS7 cells using an expression vector containing an SV40 origin of replication resulted in a greater than 50-fold increase in both menadione reductase activity and daunorubicin reductase activity, suggesting that both activities are derived from the same enzyme. Carbonyl reductase mRNA levels reflected enzyme activity levels in the transfected cells. Other parameters, such as pH profile, cofactor requirements, substrates, and inhibitors, were similar to those of carbonyl reductase purified by other investigators. Potential regulatory elements with consensus sequences for two GC boxes and the transcriptional activator protein AP-2 were present upstream of the transcriptional start site. Although the precise role of carbonyl reductase is unknown, the enzyme is involved in drug metabolism and in the reduction of activated carbonyl compounds. Its ability to act as a quinone reductase also implies a potential to modulate oxygen free radicals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1921984

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Initiation binding repressor, a factor that binds to the transcription initiation site of the histone h5 gene, is a glycosylated member of a family of cell growth regulators [corrected].

Authors:  A Gómez-Cuadrado; M Martín; M Noël; A Ruiz-Carrillo
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

3.  Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.

Authors:  G Minotti; A F Cavaliere; A Mordente; M Rossi; R Schiavello; R Zamparelli; G Possati
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

4.  Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Authors:  Giuseppe Sacco; Rossella Giampietro; Emanuela Salvatorelli; Pierantonio Menna; Nicoletta Bertani; Gallia Graiani; Fabio Animati; Cristina Goso; Carlo A Maggi; Stefano Manzini; Giorgio Minotti
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Authors:  Shuang Liang; Richard C Brundage; Pamala A Jacobson; Anne Blaes; Mark N Kirstein
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

6.  Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).

Authors:  Vanessa Gonzalez-Covarrubias; James L Kalabus; Javier G Blanco
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

Review 7.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.